ClinicalTrialsFinder

Recurrent or Refractory Disease After Standard Therapies Clinical Trials in Shenzhen, Guangdong

1 recruitingShenzhen, Guangdong, China

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)

Primary Peritoneal CarcinomaFallopian Tube CarcinomaEpithelial Ovarian Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07480954